Financiere des Professionnels Fonds d investissement inc. Sells 1,880 Shares of Stryker Corporation (NYSE:SYK)

Financiere des Professionnels Fonds d investissement inc. cut its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 8.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,626 shares of the medical technology company's stock after selling 1,880 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.'s holdings in Stryker were worth $8,050,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital A Wealth Management LLC bought a new position in Stryker during the fourth quarter worth $26,000. Rakuten Securities Inc. boosted its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Stryker in the first quarter valued at $32,000. City Holding Co. lifted its stake in shares of Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares in the last quarter. Finally, VSM Wealth Advisory LLC bought a new position in shares of Stryker in the fourth quarter valued at $36,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

NYSE SYK opened at $392.00 on Friday. The company's 50 day moving average is $382.92 and its 200-day moving average is $376.25. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. The firm has a market cap of $149.62 billion, a P/E ratio of 52.97, a price-to-earnings-growth ratio of 2.98 and a beta of 0.91. Stryker Corporation has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. Stryker's revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.50 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Analysts Set New Price Targets

A number of research firms have weighed in on SYK. Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Citigroup restated a "buy" rating and set a $455.00 price target (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Roth Mkm boosted their price target on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Truist Financial boosted their price target on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a report on Monday, May 5th. Finally, BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $427.30.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.